Symbicort is a prescription medicine used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) is owned by Astrazeneca. It contains the active ingredient Budesonide; Formoterol Fumarate Dihydrate. It was first authorized for medical use in 2006. The ashtma drug market is projected to reach US$ 38 billion in 2032. There were 21 drug patents protecting Symbicort in United States, but as of now 11 of those patents have expired.
Symbicort (Budesonide; Formoterol Fumarate Dihydrate) currently had patent protection until August 24, 2023. This means Symbicort generic become available in the market after August 24, 2023, unless a Paragraph IV certification was filed challenging the patents before expiration.
Symbicort is approved to treat asthma and chronic obstructive pulmonary disease (COPD) in patients aged 6 years and above. The active ingredients in Symbicort, Budesonide; Formoterol Fumarate Dihydrate, are a corticosteroid and a long-acting beta2-agonist bronchodilator respectively. They work by reducing airway inflammation and opening airways in the lungs to make breathing easier in patients with asthma and COPD.
Symbicort currently holds 21 patents covering various aspects, including the active ingredient, formulation, dosage, and methods of delivery. These patents expired in February and August 2023, marking a significant milestone for the medication. With these patent expirations in 2023, generic versions of Symbicort can now enter the market and compete. Below is a list of the recent Symbicort patent expirations -